Asan Institute for Life Science, Asan Medical Center, Seoul, 05505, South Korea.
Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan.
Sci Rep. 2020 Dec 8;10(1):21412. doi: 10.1038/s41598-020-77960-9.
Stemness factors control microRNA expression in cancer stem cells. Downregulation of miR-100 and miR-125b is associated with tumor progression and prognosis of various cancers. Comparing miRNA profiling of patient-derived tumorsphere (TS) and adherent (2D) hepatocellular carcinoma cells, miR-100 and miR-125b are identified to have association with stemness. In TS cells, miR-100 and miR-125b were downregulated comparing to 2D cells. The finding was reproduced in Hep3B cells. Overexpression of stemness factors NANOG, OCT4 and SOX2 by introduction of gene constructs in Hep3B cells suppressed these two miRNA expression levels. Treatment of chromeceptin, an IGF signaling pathway inhibitor, decreased numbers of TS and inhibited the AKT/mTOR pathway. Stable cell line of miR-100 and miR-125b overexpression decreased IGF2 expression and inhibited tumor growth in the xenograft model. In conclusion, miR-100 and miR-125b have tumor suppressor role in hepatocellular carcinoma through inhibiting IGF2 expression and activation of the AKT/mTOR pathway.
干性因子控制癌症干细胞中的 microRNA 表达。miR-100 和 miR-125b 的下调与多种癌症的肿瘤进展和预后相关。比较患者来源的肿瘤球(TS)和贴壁(2D)肝癌细胞的 miRNA 图谱,发现 miR-100 和 miR-125b 与干性有关。与 2D 细胞相比,TS 细胞中的 miR-100 和 miR-125b 下调。在 Hep3B 细胞中也得到了重现。通过基因构建体在 Hep3B 细胞中引入干性因子 NANOG、OCT4 和 SOX2 的过表达抑制了这两个 miRNA 的表达水平。IGF 信号通路抑制剂 chromeceptin 的处理减少了 TS 的数量并抑制了 AKT/mTOR 通路。miR-100 和 miR-125b 过表达的稳定细胞系降低了 IGF2 的表达并抑制了异种移植模型中的肿瘤生长。总之,miR-100 和 miR-125b 通过抑制 IGF2 表达和激活 AKT/mTOR 通路在肝癌中发挥肿瘤抑制作用。